Elanco Animal Health (ELAN) Net Income towards Common Stockholders (2017 - 2026)

Elanco Animal Health (ELAN) has 10 years of Net Income towards Common Stockholders data on file, last reported at $57.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 14.93% year-over-year to $57.0 million; the trailing twelve-month figure through Mar 2026 stood at -$242.0 million (down 164.88% YoY), and the FY2025 full-year result was -$232.0 million, down 168.64% from the prior year.
• Net Income towards Common Stockholders advanced to $57.0 million in Q1 2026, from -$276.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $364.0 million in Q3 2024 to a low of -$1.1 billion in Q3 2023.
• A 5-year average of -$67.4 million and a median of -$10.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 179.69% in 2022 and tumbled 3350.0% in 2025, its largest moves.
• Tracing ELAN's Net Income towards Common Stockholders over 5 years: stood at -$54.0 million in 2022, then tumbled by 161.11% to -$141.0 million in 2023, then soared by 94.33% to -$8.0 million in 2024, then plunged by 3350.0% to -$276.0 million in 2025, then jumped by 120.65% to $57.0 million in 2026.
• Business Quant data shows ELAN's Net Income towards Common Stockholders at $57.0 million in Q1 2026, -$276.0 million in Q4 2025, and -$34.0 million in Q3 2025.